跳至主要内容
临床试验/NCT05202366
NCT05202366Unknown不适用

An Open-label Cosmetic Study to Evaluate the Effectiveness of CGB-400 Topical Gel for Improving Appearance of Toenails Affected by Fungal Infection

CAGE Bio Inc.1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2022年2月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
CAGE Bio Inc.
入组人数
15
试验地点
1
主要终点
Investigator Global Assessment (IGA) of affected toenails

研究概览

简要总结

The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s).

This is an open-label, single group POC study evaluating the effectiveness of CGB-400 Topical Gel for toenail fungal growth clearing. The study consists of a 12-week period with 5 clinic visits at the following timepoints: Baseline (Day 0), and Weeks 2, 6, and 12 and post-application follow-up at Week 24. The applications could be extended for an additional 12 weeks based on PI's observations.

Approximately 15 subjects will be enrolled and subjected to application of CGB-400 Topical Gel. Subjects must be at least 18 years of age and will be selected by the concerned PI.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female ≥18 (and ≤99) at the time of Informed Consent.
  • Nail fungal infection of at least one great toe [per visual assessment by the clinical investigator]
  • Subjects who have target toenail showing 20-65% involvement as judged by the clinical investigator.
  • Subject must be physically able to reach toes to clean them and apply product.
  • Subject is willing to discontinue use of other nail fungus treatment products and nail cosmetic products for duration of this study.
  • Subject is willing and available to return for study follow up.
  • Signed written informed consent form (ICF) prior to any trial related activity (subjects must have the mental, literate, and legal ability to give a written informed consent, which must comply with the ICH GCP guidelines and local requirements.
  • Agree to take and share pictures of the treated toenails on a periodic basis during the study and follow-up period.

排除标准

  • Female subjects that are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control.
  • Known hypersensitivity or previous allergic reaction to any constituent of the Investigational Product (i.e., essential oils, fragrance, choline, phosphatidylcholine, propylene glycol, limonene, cellulose).
  • Nails with clinical evidence of no or low distal growth.
  • History or presence of another skin/nail condition/disease that is located in the treatment area(s) and might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open wounds, infection, etc.).
  • Basal cell carcinoma within 6 months of Visit
  • Uncontrolled systemic disease.
  • Foreseen unprotected and intense/excessive UV exposure during the course of the study.
  • Use of prohibited concomitant medications/procedures, as specified below in Table 2, during the study or within the defined washout periods.
  • Scheduled or planned surgical procedures during the course of the study.
  • Unable or unwilling to comply with any of the study requirements.
  • Medical or psychiatric conditions, or a personal situation, that may increase the risk associated with study participation or may interfere with interpretation of study results or subject compliance and, in the opinion of the PI, makes the subject inappropriate for study entry.
  • Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.
  • Exposure to any other investigational drug/device within 30 days prior to study entry.

研究组 & 干预措施

Treatment group

Only one treatment group (CGB-400 Topical Gel) will be used for analysis

干预措施: CGB-400 Topical Gel (Drug)

结局指标

主要结局

Investigator Global Assessment (IGA) of affected toenails

时间窗: 24 weeks

Clear 0% nail involvement 1. Almost clear 0%-≤10% nail involvement 2. Mild 10%-\<25% nail involvement 3. Moderate 25%-≤50% nail involvement 4. Severe \>50%-≤75% nail involvement

次要结局

  • Percent clear area on affected toenail/region (s)(24 weeks)
  • Visual inspection (pictures to be collected)(24 weeks)

研究者

发起方
CAGE Bio Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验